Champions Oncology Q2 service revenue rises 11% to USD 15 million

Reuters2025-12-16

<a href="https://laohu8.com/S/CSBR">Champions Oncology</a> <a href="https://laohu8.com/S/QTWO">Q2</a> service revenue rises 11% to USD 15 million

Champions Oncology Inc. reported its financial results for the second quarter (Q2) and first half $(HY)$ of fiscal 2026. For Q2, total revenue was USD 15 million, representing an 11 percent increase. Oncology services profit reached USD 7.8 million, with an oncology services margin of 52 percent. Net income for the quarter was USD 0.2 million. Adjusted EBITDA for Q2 was USD 0.8 million. For the first half of fiscal 2026, total revenue was USD 29 million, a 5 percent increase. Oncology services profit was USD 13.8 million, with a margin of 47 percent. Adjusted EBITDA for the period was USD 1.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117630) on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591662123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591662123","market":"fut","top_or_hot":-1,"title":"Champions Oncology Q2 service revenue rises 11% to USD 15 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> service revenue rises 11% to USD 15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the second quarter (Q2) and first half <a href=\"https://laohu8.com/S/HY\">$(HY)$</a> of fiscal 2026. For Q2, total revenue was USD 15 million, representing an 11 percent increase. Oncology services profit reached USD 7.8 million, with an oncology services margin of 52 percent. Net income for the quarter was USD 0.2 million. Adjusted EBITDA for Q2 was USD 0.8 million. For the first half of fiscal 2026, total revenue was USD 29 million, a 5 percent increase. Oncology services profit was USD 13.8 million, with a margin of 47 percent. Adjusted EBITDA for the period was USD 1.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117630) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Champions Oncology Q2 service revenue rises 11% to USD 15 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChampions Oncology Q2 service revenue rises 11% to USD 15 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> service revenue rises 11% to USD 15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the second quarter (Q2) and first half <a href=\"https://laohu8.com/S/HY\">$(HY)$</a> of fiscal 2026. For Q2, total revenue was USD 15 million, representing an 11 percent increase. Oncology services profit reached USD 7.8 million, with an oncology services margin of 52 percent. Net income for the quarter was USD 0.2 million. Adjusted EBITDA for Q2 was USD 0.8 million. For the first half of fiscal 2026, total revenue was USD 29 million, a 5 percent increase. Oncology services profit was USD 13.8 million, with a margin of 47 percent. Adjusted EBITDA for the period was USD 1.0 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117630) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLbBCsMl:1","article_id":"2591662123","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591662123","pubTimestamp":1765832432,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Champions Oncology Inc. reported its financial results for the second quarter  and first half  of fiscal 2026. For Q2, total revenue was USD 15 million, representing an 11 percent increase. Oncology services profit reached USD 7.8 million, with an oncology services margin of 52 percent. Net income for the quarter was USD 0.2 million. Adjusted EBITDA for Q2 was USD 0.8 million. For the first half of fiscal 2026, total revenue was USD 29 million, a 5 percent increase. Oncology services profit was USD 13.8 million, with a margin of 47 percent. Adjusted EBITDA for the period was USD 1.0 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CSBR":"Champions Oncology, Inc."},"translate_title":"Champions Oncology第二季度服务收入增长11%至1500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":0.9},"content_text":"Champions Oncology Q2 service revenue rises 11% to USD 15 million\n    \n\n        Champions Oncology Inc. reported its financial results for the second quarter (Q2) and first half $(HY)$ of fiscal 2026. For Q2, total revenue was USD 15 million, representing an 11 percent increase. Oncology services profit reached USD 7.8 million, with an oncology services margin of 52 percent. Net income for the quarter was USD 0.2 million. Adjusted EBITDA for Q2 was USD 0.8 million. For the first half of fiscal 2026, total revenue was USD 29 million, a 5 percent increase. Oncology services profit was USD 13.8 million, with a margin of 47 percent. Adjusted EBITDA for the period was USD 1.0 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117630) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591662123","isCrawlerRequest":true}